Bioactivity of Thyroid Hormone Analogs at Cancer Cells

Paul J. Davis, Heng Yuan Tang, Aleck Hercbergs, Hung Yun Lin, Kelly A. Keating, Shaker A. Mousa

研究成果: 雜誌貢獻回顧型文獻同行評審

24 引文 斯高帕斯(Scopus)


In the context of genomic thyroid hormone actions in normal (noncancer) cells that involve primary interactions with nuclear thyroid hormone receptors (TRs), L-thyroxine (T4), and 3,3′,5′-triiodo-L-thyronine (reverse T3, rT3) have little bioactivity. In terms of TRs, T4 is a prohormone from which the active nuclear ligand, 3,5,3′-triido-L-thyronine (T3), is generated by deiodination. Deaminated T4 and T3 metabolites have different genomic effects: tetraiodothyroacetic acid (tetrac) is a low grade thyromimetic derivative of T4, whereas triiodothyroacetic acid (triac), the acetic acid metabolite of T3, has substantial thyromimetic activity. In cancer cells, the cell surface receptor for thyroid hormone on integrin αvβ3 mediates non-genomic actions of thyroid hormone analogs. The integrin is expressed in large measure by cancer cells and dividing endothelial cells and has a substantially different panel of responses to thyroid hormone analogs. At αvβ3, T4 is a potent proliferative, anti-apoptotic and pro-angiogenic hormone and is the primary ligand. rT3 may also be proliferative at this site. In contrast, tetrac and triac are antagonists of T4 at αvβ3, but also have anticancer properties at this site that are independent of their effects on the binding of T4.
期刊Frontiers in Endocrinology
出版狀態已發佈 - 12月 4 2018

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝


深入研究「Bioactivity of Thyroid Hormone Analogs at Cancer Cells」主題。共同形成了獨特的指紋。